Fumaric Acid Esters for HbF Induction in Sickle Cell Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease, such as hydroxyurea, have limitations including bone marrow suppression, long-term carcinogenic concerns, and a 30% non-response rate, necessitating the development of alternative therapies with fewer side effects and greater efficacy.
Innovation Solution
Administering fumaric acid esters or their pharmacologically active salts, derivatives, or prodrugs to induce fetal hemoglobin production, optionally in combination with hydroxyurea, to increase expression of γ-globin and reduce symptoms of sickle cell disease and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxyurea is used to treat sickle cell disease, then vaso-occlusive episodes and pain are reduced, but bone marrow suppression and carcinogenic concerns occur
Solution Approach 1:
The patent changes the chemical parameter from hydroxyurea to fumaric acid esters, which have different mechanisms of action. Fumaric acid esters induce HbF production through a different biochemical pathway, achieving therapeutic efficacy while avoiding the bone marrow suppression and carcinogenic risks associated with hydroxyurea
Solution Approach 2:
The patent employs fumaric acid esters as an alternative therapeutic agent that can be used without the long-term safety concerns of hydroxyurea. The ester compounds provide effective treatment with a safer side effect profile, allowing for sustained use without cumulative toxicity
2Reliability
If hydroxyurea is used to treat sickle cell disease, then symptoms are improved, but 30% of patients do not respond to treatment
Solution Approach 1:
The patent changes the therapeutic parameter from hydroxyurea to fumaric acid esters, which work through a different mechanism (HbF induction). This parameter change expands the responsive patient population by targeting a different biochemical pathway that is effective in patients who do not respond to hydroxyurea
Solution Approach 2:
The patent positions fumaric acid esters as a universal treatment option that can benefit both hydroxyurea-responders and non-responders. The esters provide multi-functional therapy by inducing HbF production through an alternative pathway, making the treatment applicable to a broader patient population
Data Source
AI summary
Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.